2 Stocks You’ll Regret Not Buying 12 Months From Now: Eli Lilly and Company (LLY), Ovid Therapeutics Inc. (OVID)

8 analysts out of 16 Wall Street brokerage firms rate Eli Lilly and Company (NYSE:LLY) as a Buy, while 0 see it as a Sell. The rest 8 describe it as a Hold. LLY stock traded higher to an intra-day high of $127.32. At one point in session, its potential discontinued and the price was down to lows at $124.51. Analysts have set LLY’s consensus price at $124.87, effectively giving it a -0.22% projection on returns. Should the projected estimates be met, then the stock will likely hit its highest price at $145 (up 15.86% from current price levels). LLY has a 26.4% ROE, higher than the 13.23% average for the industry. The average ROE for the sector is 12.73%.

Eli Lilly and Company (LLY) currently trades at $125.15, which is lower by -1.6% its previous price. It has a total of 1.02 billion outstanding shares, with an ATR of around 2.15. The company’s stock volume rose to 5.52 million, better than 16.85 million that represents its 50-day average. A 5-day decrease of about -0.37% in its price means LLY is now 8.15% higher on year-to-date. The shares had marked a $132.13 52-week high price and the 52 week low of $77.09. Overall, it has seen a growth rate of 58.96 over the last 12 months.

Eli Lilly and Company (NYSE:LLY)’s EPS was $1.33 as reported for the December quarter. In comparison, the same quarter a year ago had an EPS of $1.14. That means that its growth in general now stands at 17%. Therefore, a prediction of $1.34 given by the analysts brought a negative surprise of -1%. LLY Dec 19 quarter revenue was $6.44 billion, compared to $6.16 billion recorded in same quarter last year, giving it a 5% growth rate. The company’s $0.28 billion revenue growth that quarter surprised Wall Street and investors will need to consider this as they assess the stock.

Ovid Therapeutics Inc. (NASDAQ:OVID) shares depreciated -0.54% over the last trading period, taking overall 5-day performance up to -1.08%. OVID’s price now at $1.84 is weaker than the 50-day average of $2.1. Getting the trading period increased to 200 days, the stock price was seen at $4.83 on average. The general public currently hold control of a total of 22.65 million shares, which is the number publicly available for trading. The total of shares that it has issued to investors is 38.66 million. The company’s management holds a total of 12.2%, while institutional investors hold about 26% of the remaining shares. OVID share price finished last trade -1.79% below its 20 day simple moving average and its downbeat gap from 200 day simple moving average is -62.18%, while closing the session with -13.57% distance from 50 day simple moving average.

Ovid Therapeutics Inc. (OVID) shares were last observed trading -83.93% down since July 16, 2018 when the peak of $11.45 was hit. Last month’s price growth of -7.07% puts OVID performance for the year now at -23.97%. Consequently, the shares price is trending higher by 8.24%, a 52-week worst price since Mar. 27, 2019. However, it is losing value with -68.81% in the last 6 months. From a technical perspective, it appears more likely that the stock will experience a Bull Run market as a result of the strong support seen recently between $1.67 and $1.75. The immediate resistance area is now $1.99 Williams’s %R (14) for OVID moved to 72 while the stochastic %K points at 30.67.

Estimated quarterly earnings for Ovid Therapeutics Inc. (NASDAQ:OVID) are around $-0.48 per share in three months through March with $-0.48 also the estimate for June quarter of the fiscal year. It means the growth is estimated at 11.11% and 9.43%, respectively. Analysts estimate full-year growth to be 10.43%, the target being $-1.89 a share. The upcoming year will see an increase in growth by percentage to -42.33%, more likely to see it hit the $-2.69 per share. The firm’s current profit margin over the past 12 months is 0%. OVID ranks higher in comparison to an average of -182.37% for industry peers; while the average for the sector is 1.52%.